Prevention of the development of catheter-associated urinary system infections in the early postoperative period
DOI: https://dx.doi.org/10.18565/urology.2023.2.13-19
A.S. Al-Shukri, A.V. Maksimova, N.I. Dub, S.V. Kostyukov, A.A. Manchenko, I.D. Mayorov, Yu. A. Ponomareva, S.B. Petrov
1) Department of Urology of FGBOU VO Pavlov First Saint Petersburg State Medical University of the Ministry of Health of the Russian Federation, Saint Petersburg, Russia;
2) FGBVOU VO S.M. Kirov Military Medical Academy of the Ministry of Defense of Russian Federation, Saint Petersburg, Russia;
3) FGBU NMRC named after V.A. Almazov of the Ministry of Health of the Russian Federation, Saint Petersburg, Russia
Background. Bladder catheterization is a common medical manipulation that is associated with the risk of complications, including catheter-associated urinary tract infection (CAUTI), which accounts for 80% of all nosocomial infections of the urological profile.
Aim. To evaluate the combined use of the biologically active additive Uronext and ceftriaxone in the prevention of the development of CAUTI in the early postoperative period in 120 patients aged 20–80 years with a Foley indwelling catheter.
Materials and methods: The patients were divided into 2 groups: in group I (n=60), D-mannose with cranberry extract and vitamin D3 as part of Uronext dietary supplement was administered orally in the form of sachets 48 hours before surgery and after surgery until urethral catheter was placed, as well as intravenous ceftriaxone 1000 mg 2 hours before surgery and in the postoperative period within 7 days. In group II (n=60), ceftriaxone monotherapy was prescribed in a similar way.
Results: According to the results of bacteriological examination of the removed urinary catheter on 3–7 days in Uronext group, bacterial growth was absent in 40 patients (66.67%, p<0.05), versus 23 cases (38.33%) in the control group.
Conclusions: The data obtained confirm the efficiency of the use of the biologically active additive Uronext in combination with an antibacterial drug, which allows to recommend this scheme in patients with an indwelling urinary catheter for the prevention of the development of CAUTI.
About the Autors
Corresponding author: A.S. Al-Shukri – Ph.D., MD, professor, Head of the Urological Department No1 (general and emergent urology) of Scientific and Research Center of Urology of Scientific and Research Institute of Surgery and Emergent Medicine, FGBOU VO Pavlov First Saint Petersburg State Medical University of the Ministry of Health of Russia, Saint Petersburg, Russia; e-mail: ad330@mail.ru
Similar Articles